1 citations
,
January 2022 in “Journal of Pharmaceutical Sciences” This study developed a stable, cosmetically appealing formulation for the topical delivery of the peptide FOL-005, enhancing skin permeation and maintaining stability by keeping the peptide solid and in a water-free environment with particle sizes under 10 µm.
April 2018 in “Journal of Investigative Dermatology” In a clinical phase I/IIa study, subcutaneous injections of the peptide FOL-005 increased hair growth by 8% and were safe for treating alopecia.
August 2016 in “Journal of Investigative Dermatology” This study observed that the osteopontin-derived peptide FOL-005 inhibited hair growth in human scalp skin models, contrary to its hair growth promotion in mice, supporting further clinical testing for excessive hair growth treatment.
April 2016 in “Journal of Investigative Dermatology” This study found that a newly developed peptide, FOL-005, significantly inhibited hair growth and counteracted minoxidil's effects in organ-cultured human male scalp skin and mouse models, without apparent toxicity.
19 citations
,
September 2019 in “British Journal of Dermatology” This study found that a novel peptide, FOL-005, derived from osteopontin, significantly inhibited hair growth in human hair follicles both ex vivo and in vivo, suggesting potential as a treatment for unwanted hair growth.
